NEW: Update on Recommendations for Use of Once-weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium Tuberculosis Infection

Dear Colleagues:

CDC has updated the 2011 recommendations for use of once-weekly isoniazid-rifapentine for 12 weeks (3HP) for treatment of latent TB infection.

The updated recommendations, published in CDC’s Morbidity and Mortality Weekly Report (MMWR)support and expand the use of an effective, yet shorter treatment regimen to reach even more people with latent TB infection.

The updated recommendation includes:

use of 3HP by directly observed therapy or self-administered therapy in persons over 2 years of age;
use of 3HP in persons 2-11 years old; and
use of 3HP in persons with latent TB infection who are living with HIV/AIDS and taking antiretroviral medications with acceptable drug-drug interactions with rifapentine.

Short course regimens, like 3HP, are preferred for reasons of convenience and higher rates of treatment completion. Treatment of latent TB infection is essential to controlling and eliminating TB in the United States because it substantially reduces the risk that latent TB infection will progress to TB disease.

CDC has new resources and tools for clinicians and patients to download and print.

Patient Education Materials:

Clinician Resources:

Be sure to check the website for more information. You can also follow us on Twitter @CDC_TB and Facebook @CDCTB

Thank you,

Division of Tuberculosis Elimination
U.S. Centers for Disease Control and Prevention

Call to Action

Find More Information on 3HP

Read the MMWR article, Update on Recommendations for Use of Once-weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium Tuberculosis Infection

Read the American Journal of Preventive Medicine, Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-Analysis